Search Results

endothelial growth factor (VEGF)-directed therapies (sorafenib, sunitinib, pazopanib, and bevacizumab) and mammalian target of rapamycin (mTOR) inhibitors (temsirolimus and everolimus). With such a large number of treatment options, selecting among them for a

(Panitumumab Efficacy in Combination With mFOLFOX6 Against Bevacizumab plus mFOLFOX6 in Metastatic CRC Subjects With Wild-Type KRAS Tumors), were further assessed in secondary analyses to include extended RAS testing ( KRAS exons 2, 3, 4; NRAS exons 2, 3

growth factor receptor (EGFR) to chemotherapy, 7 and the incorporation of other non-chemotherapy agents 8 all failed to improve survival and QOL. Recently, the addition of the anti–vascular endothelial growth factor (VEGF) antibody bevacizumab

benefit from bevacizumab? Is testing for homologous recombination deficiency (HRD)/genomic instability appropriate? What is the role of maintenance therapy with PARP inhibitors? Of note, because the treatment of advanced ovarian cancer is complex and

Bevacizumab Added Concurrently to Chemotherapy for Palpable and Operable Triple-Negative Invasive Breast Cancer Principal Investigator: Jasgit C. Sachdev, MD Condition: Triple-negative breast cancer Institutions: University of Tennessee Cancer

Carboplatin Followed By Doxorubicin Plus Cyclophosphamide With Bevacizumab Added Concurrently to Chemotherapy for Palpable and Operable Triple Negative Invasive Breast Cancer Principal Investigator: Jasgit C. Sachdev, MD Condition: Triple negative breast

analysis of the FIRE-3 trial (discussed in “ Cetuximab or Panitumumab Versus Bevacizumab in First-line Therapy ,”) has been published. 30 When all RAS ( KRAS/NRAS ) mutations were considered, PFS was significantly worse in patients with RAS -mutant

nab-paclitaxel for PFS. Statistical superiority was also reported for pembrolizumab+paclitaxel compared to paclitaxel (for OS and PFS), paclitaxel+ bevacizumab (for OS) and ixabepilone+bevacizumab (for OS). Conclusions : These analyses suggest

critical therapies with the potential to lower cost of care. There are 9 FDA approved therapeutic oncology biosimilars to 3 reference molecules: trastuzumab (5), bevacizumab (2) and rituximab (2), in addition to supportive care biosimilars for hematopoietic

as bevacizumab and pembrolizumab is difficult in this patient population, because bevacizumab and pembrolizumab are not widely available, are expensive, and require specific expertise to be delivered. Despite their improved activity over traditional